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Abstract
Background: Previous studies showed that at the individual level, positron emission tomography
(PET) has some benefits for patients and physicians in terms of cancer management and staging. We
aimed to describe the benefits of (PET) in the management of solitary pulmonary nodules (SPNs)
in a population level, in terms of the number of diagnostic and invasive tests performed, time to
diagnosis and factors determining PET utilization.
Methods:  In an observational study, we examined reports of computed tomography (CT)
performed and mentioning "spherical lesion", "nodule" or synonymous terms. We found 11,515
reports in a before-PET period, 2002–2003, and 20,075 in an after-PET period, 2004–2005. Patients
were followed through their physician, who was responsible for diagnostic management.
Results: We had complete data for 112 patients (73.7%) with new cases of SPN in the before-PET
period and 250 (81.4%) in the after-PET period. Patients did not differ in mean age (64.9 vs. 64.8
years). The before-PET patients underwent a mean of 4 tests as compared with 3 tests for the after-
PET patients (p = 0.08). Patients in the before-PET period had to wait 41.4 days, on average, before
receiving a diagnosis as compared with 24.0 days, on average, for patients in the after-PET period
who did not undergo PET (p < 0.001). In the after-PET period, 11% of patients underwent PET
during the diagnostic process. A spiculated nodule was more likely to determine prescription for
PET (p < 0.001). Multivariate analysis revealed that patients in both periods underwent fewer tests
when PET was prescribed by general practitioners (p < 0.001) and if the nodule was not spiculated
Published: 11 May 2009
BMC Cancer 2009, 9:139 doi:10.1186/1471-2407-9-139
Received: 9 September 2008
Accepted: 11 May 2009
This article is available from: http://www.biomedcentral.com/1471-2407/9/139
© 2009 Lemonnier et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2009, 9:139 http://www.biomedcentral.com/1471-2407/9/139
Page 2 of 10
(page number not for citation purposes)
(p < 0.001). The proportion of unnecessary invasive approaches prescribed (47% vs. 49%) did not
differ between the groups.
Conclusion: In our study, 1 year after the availability of PET, the technology was not the first
choice for diagnostic management of SPN. Even though we observed a tendency for reduced
number of tests and mean time to diagnosis with PET, these phenomena did not fully relate to PET
availability in health communities. In addition, the availability of PET in the management of SPN
diagnosis did not reduce the overall rate of unnecessary invasive approaches.
Background
A solitary pulmonary nodule (SPN) is a single spherical
lesion < 3 cm in diameter completely surrounded by lung
tissue without associated atelectasis or adenopathy [1,2].
In most cases, it is detected incidentally by chest x-ray
(CXR) imaging or computed tomography (CT). No data is
available on its incidence in a general population, but
about 1 of 500 CXR images in the United States reveals a
nodule [3]. The frequency of SPN malignancy depends on
the population where it is estimated, about 26% to 40%
in the US [4,5] and 40% in France [6]. Therefore, SPN is
often associated with lung cancer, a major public health
problem, with 25,882 new cases and 27,164 deaths
reported in France in 2000 [7].
The management of SPN diagnosis consists of combina-
tions of different approaches, invasive and/or noninva-
sive, from the moment SPN is identified by CXR or CT
until the definitive diagnosis of its nature – malignant or
benign. This diagnostic approach depends on characteris-
tics of patients (age, smoking history, antecedents of can-
cer) and nodules (size, location, spiculation, and
calcification within the nodule). These characteristics
determine the probability of malignancy [4,8]. One exam-
ple of a malignant nodule is a new nodule of large size in
an older patient with a heavy smoking history and CXR or
CT results of a spiculated nodule pattern [9].
The newest imaging technology in nuclear medicine, pos-
itron emission tomography (PET), was introduced in
oncology. It is also used in differentiating the nature of
pulmonary nodules. Many studies concerning the per-
formance of PET or PET scanning reported the sensitivity,
specificity, and accuracy of this technique as 96%, 88%,
and 94%, respectively, in the diagnosis of benign nodules
[10-14]. Meanwhile, decision model analysis concerning
the management of SPN diagnosis or studies investigating
the combination of certain diagnostic tests showed that
the sensitivity and specificity of the combination of exam-
inations, with or without PET, varies depending on the
type of examination performed for each patient and nod-
ule [4,15-19]. Some techniques, such as transbronchic
and transthoracic procedures, entail risk of complications
(pneumothorax or haemorrhage) [18,20]. These proce-
dures are considered unnecessary when the nodule proves
later to be benign. The physician aims to prescribe the
most appropriate examination to effectively diagnose the
nature of the nodule, whether benign or malignant, and
to avoid morbidity and/or mortality due to unnecessary
invasive explorations [21]. The use of PET could reduce
those risks by avoiding unnecessary explorations.
Research into the ability of PET to differentiate malignant
from benign nodules have proved its good performance at
the individual level compared to other imaging technolo-
gies such as CT or magnetic resonance imaging (MRI).
Results of PET could change the cancer's staging or physi-
cians' decision for further exploration in cancer manage-
ment [22]. Unfortunately, few studies are available on
changes in the management of SPN diagnosis that PET
brings in real-life practice at a population level. Knowing
whether the availability of PET contributes to altering the
number of tests performed and avoiding unnecessary
invasive approaches for patients with benign nodules in
routine practice is important for patients and for physi-
cians.
Therefore, we aimed to study the actual practice of man-
aging the diagnosis of SPN before PET was introduced in
France as a diagnostic test (2002–2003; before-PET) and
after its introduction (2004–2005; after-PET) – a before-
after study. We aimed to describe the modifications in the
management of SPN diagnosis in daily practice in terms of
average number of tests performed, time to diagnosis and
proportion of unnecessary invasive tests performed with
PET availability in the 5 northeastern regions of France.
We also identified determinants of the use of PET in the
after-PET period and the use of invasive approaches in
both periods.
Methods
The study was approved by the Institutional Review Board
(Commission National d'Informatique et Liberté [CNIL])
in January 2002. PET was available for use in 5 regions in
northeastern France (Alsace, Lorraine, Franche-Comté,
Bourgogne, and Champagne-Ardenne), 18 health admin-
istrative districts covering 8,220,000 people [23], in
2003–2004. We collected data on the before-PET period
between May 2002 and March 2003 and on the after-PET
period between June 2004 and June 2005. The before-PETBMC Cancer 2009, 9:139 http://www.biomedcentral.com/1471-2407/9/139
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period was shorter because of the limited time before PET
availability in each region.
Study Samples
Periods of 4–8 weeks, with duration adjusted to the pop-
ulation size and number of CT centres in each region,
were randomly sampled on the year's calendar to equally
balance the number of patients included in each region.
Qualified research assistants examined 31,590 CT reports,
compiled by the radiologists in each centre. They exam-
ined 11,515 reports in the before-PET period and 20,075
in the after-PET period, in all (76) CT centres in the 5
regions. We identified new SPN cases from CT reports that
mentioned "spherical lesion" or "nodule" or synonymous
terms (including "mass" or "solitary mass", "solitary pul-
monary nodule" or "SPN"), A panel of investigators veri-
fied all included cases.
We included patients who were ≥ 18 years old, had a nod-
ule of 1 to 3 cm in diameter, were without antecedent can-
cer, and followed the diagnostic management in all care
centres involved in the 5 regions. Patients were not
included if they had multiple nodules, or who underwent
the diagnostic management outside of the 5 study regions.
Studies reported that one of the major benefits of PET was
a reduction in the number of patients referred for surgery.
Depending on the pre-test probability of malignant dis-
ease, the use of PET decreased the performance of surgical
procedures by an estimated 15% [24]. To observe a differ-
ence of at least 15% between both periods in terms of
invasive approaches for patients with benign nodules and
for a power of at least 80%, we doubled the number of
patients included in the after-PET period. This step was
necessary because the before-PET period entailed time
constraints before the introduction of PET and we could
include only a limited number of patients.
Data collection
A research assistant in each region collected data on socio-
demographic characteristics of patients such as age, sex,
and smoking history; and nodule characteristics, such as
calcification within the nodule, appearance of spiculated
nodule, and mediastinal involvement or enlarged lymph
nodes seen on CT. Information on examinations and
treatments that were prescribed during 6-month follow-
up was collected as well.
We defined the beginning of the diagnostic management
as the date of the CT report identifying the nodule. We
considered that the presumptive diagnosis of cancer was
established when physicians who handled the manage-
ment of the diagnosis decided to discontinue the diagno-
sis process and to begin surveillance for benign nodules or
treatments for malignant nodules. We followed all
patients for 6 months after the presumptive diagnosis
through the hospital or the physician who was in charge
of managing the diagnosis. Diagnostic management was
considered specialised if performed by a radiologist, chest
physician, oncologist or thoracic surgeon.
The number of tests were those prescribed by a physician
for a given patient from the beginning of the diagnostic
management until the presumptive diagnosis. The diag-
nostic management was defined as the combination of
examinations in chronological order from the identifica-
tion of SPN on CT up to the presumptive diagnosis of
SPN. We defined invasive approaches as any combination
of tests involving at least one nonimaging examination.
Unnecessary invasive approaches were defined as those
involving one or more invasive explorations in which the
nodule was later diagnosed to be benign.
Statistical Analysis
We used the chi-square test to compare samples, nodule
characteristics, and proportion of unnecessary invasive
approaches between the two periods. The Mann-Whitney
test was used to compare mean age, mean number of diag-
nostic tests and time to diagnosis between periods. Results
are expressed as percentages, means, and standard devia-
tions (SDs). We tested the relation between number of
diagnostic examinations and other variables in each
period by multiple regression analysis. We used logistic
regression models to identify the determinants of (1)
invasive approaches in both periods, and (2) determinant
factors for PET use for the after-PET period. A P < 0.05 was
considered statistically significant for all analyses. The
combination of SPN diagnostic tests in both periods was
identified by use of SLPMiner, a data-mining algorithm
for finding frequent sequential patterns [25,26] (i.e., time-
ordered sequences of diagnostic tests performed for
patients). The most frequent sequential patterns are iden-
tified as strategies and are presented as percentages. We
described diagnostic test combinations that took place in
5% or more of cases in both periods.
The data were recorded in a Microsoft ACCESS database,
and statistical tests involved use of SAS V 9.1 (SAS Inst.,
Cary, NC).
Results
Patient and nodule characteristics
A total of 459 patients with new cases of SPN (152 before-
PET and 307 after-PET) were included. Of all patients
included in both periods, 362 patients completed the
study: 112 before-PET patients (73.7%), and 250 after-
PET patients (81.4%). Eight patients died before a pre-
sumptive diagnosis, 10 patients refused further examina-
tions, and 77 were lost to follow-up (Figure 1).
A greater proportion of patients with smoking history
completed the study as compared with those who wereBMC Cancer 2009, 9:139 http://www.biomedcentral.com/1471-2407/9/139
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lost to follow-up for both the before-PET (p = 0.002) and
after-PET periods (p < 0.001). Patients whose diagnostic
management was handled by specialists showed a more
frequent tendency to have complete information for the
study than those who were lost to follow-up in the after-
PET period (p = 0.02). No other differences were observed
in patient or nodule characteristics.
Patients in the before-PET and after-PET periods did not
differ in age (mean 64.9 years [SE 14.1] vs. 64.8 years [SE
14.3]). Smoking habit differed between the two periods
(58.4% for after-PET vs. 70.5% for before-PET; p = 0.03).
Physicians tended to identify more calcified nodules and
less spiculated nodules on CT results in the after-PET than
before-PET period; the difference was not statistically sig-
nificant (Table 1).
Management of SPN diagnosis
Patients in the before-PET period underwent a mean
number of 4 tests before the presumptive definitive diag-
nosis of the nodule as compared to a mean of 3 tests in the
after-PET period, but the difference was not statistically
significant (p = 0.08). Table 2 describes mean number of
tests according to patients and nodule characteristics in
both periods. In the after-PET period, physicians pre-
scribed a mean number of 5 tests for patients who under-
went PET as compared to a mean of 3 tests for those who
did not undergo PET (p < 0.001). Multivariate analysis
showed that for both periods, patients who were referred
by specialists and had spiculated nodules underwent
more tests than patients who were referred by general
practitioners and had nonspiculated nodule features
(Table 3).
Patients in the before-PET period had to wait 41.4 days,
on average, before receiving a presumptive diagnosis as
compared with 24.0 days, on average, for patients in the
after-PET period who did not undergo PET (p < 0.001);
those who underwent PET had to wait 56.7 days, on aver-
age, for a diagnosis. Bivariate analysis showed that
patients who were male, were smokers, and had calcified
and spiculated nodules were more likely to undergo PET.
The number of patients in both periods Figure 1
The number of patients in both periods.
      Before-PET period (2002 – 2003)            After-PET period (2004-2005) 
20,075 CT 
reports
250 patients 
had complete 
information 
2 patients died 
49 patients lost 
to follow up
4 patients refused 
further
investigation
307 patients 
with SPN 
included
6 patients died 
28 patients 
lost to follow 
up
6 patients 
refused further 
investigation 
11,515 CT 
reports
152 patients 
with SPN 
included
112  patients 
had complete 
information BMC Cancer 2009, 9:139 http://www.biomedcentral.com/1471-2407/9/139
Page 5 of 10
(page number not for citation purposes)
Multivariate analysis revealed that only spiculated nod-
ules played a significant role in determining whether
patients underwent PET (p < 0.001) (Table 4). The mean
number of diagnostic tests in patients with spiculated
nodules did not differ between the periods (5.3 for before-
PET vs. 5.1 for after-PET; p = 0.4).
Invasive approaches were more likely to be prescribed by
specialists (p = 0.002) for smokers or ex-smokers (p <
0.001) with spiculated (p < 0.001) and noncalcified nod-
ules (p < 0.001), but the proportion of patients undergo-
ing at least one invasive test in the two periods did not
differ (47% for before-PET vs. 49% for after-PET). In the
after-PET period, of 185 patients with benign nodules, 54
(29.2%) underwent at least one invasive test, most fre-
quently associated with PET (p < 0.001).
The proportion of patients undergoing CT of the thorax,
bronchial fibroscopy, abdominal CT, and bone scintigra-
phy was almost similar in both periods. Less than 5% of
patients in the after-PET period underwent lung scintigra-
phy, thoracotomy, and gastroscopy (Table 5). A total of
11% of patients underwent CXR as one of the diagnostic
tests in the after-PET period as compared with 30% in the
before-PET period (p < 0.001). A combination of CT of
the thorax followed by bronchial fibroscopy was per-
formed for almost the same proportion of patients in both
periods (35.8% for before-PET vs. 33.7% for after-PET).
However, a combination of abdominal echography and
CT of the thorax was performed for less than 5% of
patients in the after-PET period as compared with 16.7%
in the before-PET period. In the after-PET period, physi-
cians prescribed PET for 11% of patients, and 8% of them
also underwent bronchial fibroscopy.
Of all patients included in the after-PET period, 62
(25.2%) had a diagnosis of cancer as compared with 30
(26.8%) in the before-PET period. Of 35 patients who
Table 1: Patient and nodule characteristics in the periods Before (2002–2003) and After (2004–2005) the availability of Positron 
Emission Tomography (PET)
Variable Before-PET period After-PET period p
Mean [SD] n (%) Mean [SD] n (%)
Patient characteristics:
Age 64.9 [14.1] 112 64.8 [14.3] 250 0.9
Age (in classes)
< 65 years 52 (46.4) 124 (49.6) 0.6
≥ 65 years 60 (53.6) 126 (50.4)
Sex
Male 82 (73.2) 158 (63.2) 0.06
Female 30 (26.8) 92 (36.8)
Referal
General practitioner 18 (16.1) 28 (11.2) 0.2
Specialist 94 (83.9) 222 (88.8)
Smoking history
Nonsmoker 33 (29.5) 104 (41.6) 0.03
Smokers or ex-smokers 79 (70.5) 146 (58.4)
Nodule characteristics:
Calcified Nodules
Yes 12 (10.7) 45 (18.0) 0.08
No 100 (89.3) 205 (82.0)
Spiculated Nodules
Yes 32 (28.6) 49 (19.6) 0.06
No 80 (71.4) 201 (80.4)
Mediastinal node
Yes 31 (27.7) 75 (30.0) 0.7
No 81 (72.3) 175 (70.0)
SD = standard deviationBMC Cancer 2009, 9:139 http://www.biomedcentral.com/1471-2407/9/139
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underwent PET as one of their diagnostic tests, for 19
(54.3%), malignant nodules were revealed and for 11
(31.4%) no such diagnosis was made. Physicians pre-
scribed PET to search for metastases in 4 patients (11.4%),
and for 1 patient, PET was prescribed after the nodule was
identified to be noncancerous.
Eighteen patients (29%) with a diagnosis of cancer under-
went further lobectomy, bilobectomy or pneumonectomy
for treatment, and these surgeries also served as diagnostic
tests for 3 of the patients. Four patients underwent chem-
otherapy or radiotherapy in addition to surgery. Of all
patients who received surgical treatments, one patient
died about 1 year later due to brain, liver and lung metas-
tases.
Discussion
We found that the mean number of diagnostic tests per-
formed for the management of SPN diagnosis declined
after PET was introduced into the northeastern regions of
France, but the reduction was not statistically significant.
The mean number of diagnostic tests was fewer if pre-
scribed by general practitioners and if the nodule was cal-
cified or not spiculated. The reduction in mean number of
diagnostic tests and time to presumptive diagnosis
seemed to relate to study period rather than to use of PET.
Physicians in the after-PET period seemed to prescribe less
CXR and abdominal echography than in the before-PET
period. This change was likely due to a generalisation and
improvement of technology in that CT is considered more
sensitive and specific than CXR in differentiating nodule
status [1,9,27].
Even if the proportion of invasive tests performed did not
differ between the two periods, unnecessary invasive
approaches (i.e., invasive examination for patients with
benign nodules) were less likely to be prescribed for patients
who had undergone PET in the after-PET period. PET seemed
Table 2: Mean number of diagnostic tests prescribed in the periods Before and After the availability of Positron Emission Tomography 
(PET)
Variables Before-PET period (n = 112) After-PET period (n = 250)
Mean (SD) p Mean (SD) p
Patients
Age (in classes)
< 65 years 3.8 (3.2) 0.6 3.5 (2.5) 0.04
≥ 65 years 4.7 (5.2) 2.9 (2.2)
Sex
Male 4.6 (4.8) 0.3 3.5 (2.5) < 0.01
Female 3.5 (2.8) 2.5 (1.9)
Referal
General practitioner 2.2 (1.9) < 0.01 1.7 (1.3) < 0.01
Specialist 4.7 (4.6) 3.3 (2.3)
Smoking history
Nonsmoker 3.2 (4.2) < 0.01 2.4 (1.9) < 0.01
Smokers or ex-smokers 4.8 (4.4) 3.6 (2.5)
Nodules
Calcified Nodules
Yes 3.1 (4.5) 0.049 2.2 (1.6) < 0.01
No 4.5 (4.4) 3.4 (2.4)
Spiculated Nodules
Yes 5.3 (4.3) 0.048 4.9 (2.7) < 0.01
No 3.9 (4.4) 2.7 (2.0)
Mediastinal node
Yes 4.5 (4.9) 0.9 3.7 (2.5) < 0.01
No 4.3 (4.2) 2.9 (2.2)
SD = standard deviation
p = Wilcoxon (Mann-Whitney) testBMC Cancer 2009, 9:139 http://www.biomedcentral.com/1471-2407/9/139
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to be prescribed when physicians considered a higher prob-
ability of malignancy of the nodule (spiculated) or to iden-
tify distal metastases. This finding confirmed the use of PET
to differentiate malignant from benign nodules.
Both periods exhibited similar proportions of combina-
tions of tests used. The management of SPN diagnosis for
patients who underwent PET as one of their diagnostic
tests in routine practice tended to confirm experimental
conditions at the individual level. We found that 1 year
after its availability, PET was not the immediate choice in
daily practice, and therefore the frequency of PET prescrip-
tion was quite low. Physicians tended to prescribe other
techniques, even if invasive, that could be accessed imme-
diately before prescribing PET, which was available only
in the largest hospital in the region.
One study showed that PET as a noninvasive test was as
efficacious as transthoracic aspiration needle biopsy in
identifying malignant lung lesions and entailed no risk of
complications [16]. Results of a retrospective Swiss study
suggested that a combination of flexible bronchoscopy
and PET had a useful role in the diagnosis of noncalcified
chest lesions less than 3 cm seen on radiography and that
bronchoscopy should be a first step because it allowed for
a tissue diagnosis, was safe, and was more readily availa-
ble [15]. Other studies of decision analysis models
showed that CT-PET was the most cost-effective strategy in
the management of SPN diagnosis [21,28]. In our study,
1 year after PET was made available, 11% of patients
underwent this technology. One of the limitations of this
study is that the onset of the after-PET observation period
was too early and therefore the time interval for study was
too short. Perhaps PET was not readily accessible for some
patients because of the limited number of machines or the
diffusion of information of the utilisation of PET was not
fast enough to change physicians' habits in management
of SPN diagnosis. However, like the Swiss study findings,
in our study, PET was always performed at least after CT
or after CT and bronchoscopy.
Table 3: Factors Iinfluencing the number of diagnostic tests patients with a Solitary Pulmonary Nodule underwent Before and After 
the availability of Positron Emission Tomography (PET) (n = 362)
Variables Bivariate analysis Multivariate analysis
β (SE) p β (SE) p
Period
Before-PET - -
After-PET -1.2 (0.4) < 0.01 -0.96 (0.3) < 0.01
Age (in classes)
< 65 years - -
≥ 65 years -0.1 (0.3) 0.8 0.2 (0.3) 0.6
Sex
Female - -
Male 1.1 (0.3) < 0.01 0.6 (0.4) 0.1
Referal
General practitioner - -
Specialist 1.8 (0.5) < 0.01 1.8 (0.5) < 0.01
Smoking history
Nonsmoker - -
Smokers or ex-smokers 1.4 (0.3) < 0.01 0.5 (0.4) 0.2
Calcified Nodules
Yes - -
No 1.4 (0.5) < 0.01 0.6 (0.4) 0.1
Spiculated Nodules
Yes - -
No -1.9 (0.3) < 0.01 -1.5 (0.4) < 0.01
Mediastinal node
Yes - -
No -0.6 (0.4) 0.09 -0.3 (0.4) 0.5
SE = standard errorBMC Cancer 2009, 9:139 http://www.biomedcentral.com/1471-2407/9/139
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Table 4: Factors influencing the performance of Positron Emission Tomography (PET) in the period After PET was available (2004–
2005) (n = 250)
Variable Bivariate Multivariate
Odds Ratio CI p Odds Ratio CI p
Age (in classes)
< 65 years 1 0.06 1 0.5
≥ 65 years 0.4 0.2 – 1.0 0.5 0.5 – 4.2
Sex
Female 1 0.04 1 0.1
Male 2.5 1.0 – 6 1.5 0.2 – 1.1
Referal
General practitioner 1 0.1 1 0.2
Specialist 4.7 0.6 – 35 3.7 0.5 – 29.7
Smoking history
Nonsmoker 1 < 0.01 1 0.4
Smokers or ex-smokers 3.9 1.5 – 9.7 1.6 0.5 – 4.6
Calcified Nodules
Yes 1 0.04 1 0.1
No 8.4 1.1–63 5.2 0.7 – 41.1
Spiculated Nodules
Yes 1 < 0.01 1 < 0.01
No 0.2 0.1 – 0.3 0.2 0.1 – 0.5
Mediastinal node
Yes 1 0.1 1 0.5
No 0.6 0.3 – 1.2 0.8 0.3 – 1.7
CI = Confidence Interval
Logistic regression analysis of the probability of patients undergoing PET as one of diagnostic tests
Table 5: Diagnostic tests performed in the periods Before and After the availability of Positron Emission Tomography (PET)
Type of diagnostic tests Before-PET (112) After-PET (250)
n (%) n (%)
CT of the thorax 108 (96.7) 248 (99.2)
Bronchial fibroscopy 48 (42.5) 94 (37.5)
CT of the abdomine 37 (33.3) 79 (31.5)
CXR 34 (30.0) 27 (10.9)
CT of the skull 25 (22.5) 42 (16.9)
Abdominal echography 24 (21.7) 21 (8.5)
Bone scintigraphy 14 (12.5) 22 (8.9)
Transparietal ponction 12 (10.0) 15 (6.0)
Pulmonary scintigraphy 6 (5.0) 9 (3.6)
Thoracotomy 6 (5.0) 9 (3.6)
Gastroscopy 6 (5.0) 4 (1.6)
PET 0 - 27 (10.9)
Identified by use of SLPMiner. CT = computed tomography; CXR = chest x-rayBMC Cancer 2009, 9:139 http://www.biomedcentral.com/1471-2407/9/139
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Results of many studies of PET performance in the diagno-
sis of SPN showed its superiority as compared with CXR
or CT in differentiating malignant from benign nodules.
Since randomizing patients to PET or non-PET groups is
unethical, we decided to use a before-and-after design to
evaluate any modification that might occur in the man-
agement of SPN diagnosis within participating regions.
We considered a design that could also reduce a possible
centre effect bias by incorporating all imaging centres in
this large area.
We followed patients for 6 months after the presumptive
diagnosis of their nodule considering that should the
nodule's volume double in that period, the probability of
its malignancy was high. Benign nodules are well known
to have a longer doubling time than malignant nodules
[12]. Some studies showed that for most malignant nod-
ules, the volume doubling time is less than 400 days, with
an average of 100 days in most cases [29-31]. Some stud-
ies suggested that the probability of nodule malignancy
could be predicted from information on patient and nod-
ule characteristics [17,32]. In daily practice, information
on nodule size and its localisation, which could help phy-
sicians in the management of SPN diagnosis, was not
always available on CT reports. Therefore, standardizing
CT reports to include nodule characteristics (size, localisa-
tion, spiculation, calcification, and mediastinal node)
would be useful.
Our study contained some limitations, such as a risk of
measurement bias should any of the CT centres change
instruments (CT camera) used to identify the SPN. To
anticipate this potential bias, we asked each region to
report any modification that might take place within or
between the study periods. Some regions reported that
new CT centres were opened between periods, and we
included those centres as starting points to identify
patients in the second period, but no major instrument
changes were reported. Another limitation is that the
after-PET period was probably still an implementation
period in which prescription behaviours were not yet con-
solidated. Further observation after 3 years or more might
allow for observing more use of PET.
Research studies showed that PET was more sensitive and
more specific than other imaging techniques and more
cost-effective than other strategies in diagnosing SPN
[21,33,34]. However, in daily practice, PET did not
directly contribute to the reduction in mean number of
diagnostic tests or time to diagnosis. Its use did not reduce
the frequency of unnecessary invasive examinations per-
formed. In other words, use of PET brings clinical benefits
to individual patients because of its performance, but at a
population level, its benefits were not immediately
observed and were of limited magnitude.
Conclusion
This is the first study to evaluate the management of SPN
diagnosis before and after the introduction of PET in a
community. Despite the benefits that individual patients
may experience, 1 year after the introduction of PET in
oncology, clinicians do not yet allow a significant place
for PET in the daily management of SPN diagnosis. Fur-
ther study could be useful to evaluate the cost savings of
actual modified practices and benefit for the health care
system.
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